397 related articles for article (PubMed ID: 11380038)
1. Efficacy and safety of repeated infliximab infusions for Crohn's disease: 1-year clinical experience.
Cohen RD
Inflamm Bowel Dis; 2001 May; 7 Suppl 1():S17-22. PubMed ID: 11380038
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Infliximab Therapy and Predictors of Response in Korean Patients with Crohn's Disease: A Nationwide, Multicenter Study.
Choi CH; Song ID; Kim YH; Koo JS; Kim YS; Kim JS; Kim N; Kim ES; Kim JH; Kim JW; Kim TO; Kim HS; Kim HJ; Park YS; Park DI; Park SJ; Song HJ; Shin SJ; Yang SK; Ye BD; Lee KM; Lee BI; Lee SY; Lee CK; Im JP; Jang BI; Jeon TJ; Cho YK; Chang SK; Jeon SR; Jung SA; Jeen YT; Cha JM; Han DS; Kim WH;
Yonsei Med J; 2016 Nov; 57(6):1376-85. PubMed ID: 27593865
[TBL] [Abstract][Full Text] [Related]
3. Infliximab in Crohn's disease: first anniversary clinical experience.
Cohen RD; Tsang JF; Hanauer SB
Am J Gastroenterol; 2000 Dec; 95(12):3469-77. PubMed ID: 11151879
[TBL] [Abstract][Full Text] [Related]
4. Infliximab for Crohn's disease in clinical practice: the experience of a single center in romania.
Gheorghe L; Gheorghe C; Badea M; Vădan R; Pârvulescu I; Toader C; Tugui L; Papuc O; Ionescu R; Preda C; Călin I; Diculescu M
Rom J Gastroenterol; 2003 Mar; 12(1):7-13. PubMed ID: 12673373
[TBL] [Abstract][Full Text] [Related]
5. Infliximab treatment for Crohn's disease: one-year experience in a Dutch academic hospital.
Hommes DW; van de Heisteeg BH; van der Spek M; Bartelsman JF; van Deventer SJ
Inflamm Bowel Dis; 2002 Mar; 8(2):81-6. PubMed ID: 11854604
[TBL] [Abstract][Full Text] [Related]
6. Infliximab in treatment of Crohn's disease: the Milan experience.
Ardizzone S; Colombo E; Maconi G; Bollani S; Manzionna G; Petrone MC; Bianchi Porro G
Dig Liver Dis; 2002 Jun; 34(6):411-8. PubMed ID: 12132788
[TBL] [Abstract][Full Text] [Related]
7. Clinical experience with infliximab therapy in 100 patients with Crohn's disease.
Farrell RJ; Shah SA; Lodhavia PJ; Alsahli M; Falchuk KR; Michetti P; Peppercorn MA
Am J Gastroenterol; 2000 Dec; 95(12):3490-7. PubMed ID: 11151882
[TBL] [Abstract][Full Text] [Related]
8. Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study.
Jahnsen J; Detlie TE; Vatn S; Ricanek P
Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():45-52. PubMed ID: 26395534
[TBL] [Abstract][Full Text] [Related]
9. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
[TBL] [Abstract][Full Text] [Related]
10. Immunomodulators and "on demand" therapy with infliximab in Crohn's disease: clinical experience with 400 infusions.
Kinney T; Rawlins M; Kozarek R; France R; Patterson D
Am J Gastroenterol; 2003 Mar; 98(3):608-12. PubMed ID: 12650795
[TBL] [Abstract][Full Text] [Related]
11. [Efficacy and safety of treatment with infliximab in Crohn's disease-the experience of single center in Korea].
Choi KD; Song HJ; Kim JS; Jung HC; Song IS
Korean J Gastroenterol; 2005 Jul; 46(1):48-55. PubMed ID: 16030404
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of Crohn disease in adults with tumor necrosis factor-alpha (TNF-alpha) antibodies].
Belaiche J; Louis E
Rev Med Liege; 2000 Sep; 55(9):827-32. PubMed ID: 11105596
[TBL] [Abstract][Full Text] [Related]
13. Infliximab use in luminal Crohn's disease.
Richter JA; Bickston SJ
Gastroenterol Clin North Am; 2006 Dec; 35(4):775-93. PubMed ID: 17129813
[TBL] [Abstract][Full Text] [Related]
14. [Indications and results of infliximab in Crohn's disease].
Karoui S; Boubaker J; Filali A
Tunis Med; 2004 Dec; 82(12):1057-63. PubMed ID: 15822505
[TBL] [Abstract][Full Text] [Related]
15. The impact of infliximab induction therapy on mucosal healing and clinical remission in Polish pediatric patients with moderate-to-severe Crohn's disease.
Kierkus J; Dadalski M; Szymanska E; Oracz G; Wegner A; Gorczewska M; Szymanska S; Woynarowski M; Ryzko J
Eur J Gastroenterol Hepatol; 2012 May; 24(5):495-500. PubMed ID: 22387887
[TBL] [Abstract][Full Text] [Related]
16. Adalimumab for Crohn's disease after infliximab treatment failure: a systematic review.
Da W; Zhu J; Wang L; Lu Y
Eur J Gastroenterol Hepatol; 2013 Aug; 25(8):885-91. PubMed ID: 23817447
[TBL] [Abstract][Full Text] [Related]
17. Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea.
Park SH; Kim YH; Lee JH; Kwon HJ; Lee SH; Park DI; Kim HK; Cheon JH; Im JP; Kim YS; Lee SY; Lee SJ
Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():35-44. PubMed ID: 26395533
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting.
Trinder MW; Lawrance IC
J Gastroenterol Hepatol; 2009 Jul; 24(7):1252-7. PubMed ID: 19220669
[TBL] [Abstract][Full Text] [Related]
19. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.
Baert F; Noman M; Vermeire S; Van Assche G; D' Haens G; Carbonez A; Rutgeerts P
N Engl J Med; 2003 Feb; 348(7):601-8. PubMed ID: 12584368
[TBL] [Abstract][Full Text] [Related]
20. Austrian infliximab experience in Crohn's disease: a nationwide cooperative study with long-term follow-up.
Wenzl HH; Reinisch W; Jahnel J; Stockenhuber F; Tilg H; Kirchgatterer A; Petritsch W
Eur J Gastroenterol Hepatol; 2004 Aug; 16(8):767-73. PubMed ID: 15256978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
